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Purpose: We evaluated and compared the efficacy of tamsulosin and alfuzosin in the 
medical treatment of symptomatic, uncomplicated distal ureteral stones.
Materials and Methods: A total of 87 patients with distal ureteral stones of ≤10 mm 
were randomly divided into 3 groups. Group I patients (n=29) received 0.4 mg tamsulo-
sin daily, group II patients (n=30) received 10 mg alfuzosin daily, and group III patients 
(n=28) were not given tamsulosin or alfuzosin. Patients in all groups received 
Diclofenac sodium regularly for 1 week and then on demand. Follow-up was done on 
a weekly basis for 30 days.
Results: The mean stone size was comparable in the 3 groups (4.97±2.24, 5.47±2.13,
and 5.39±1.81 mm, respectively). The stone expulsion rate was 86.2%, 76.6%, and 50% 
in groups I, II, and III, respectively. The difference in groups I and II with respect to 
group III was significant (p=0.0028 and 0.035). The mean expulsion time for groups 
I to III was 7.52±7.06, 8.26±7.34, and 13.90±6.99 days, respectively. The expulsion time 
was significantly shorter in groups I and II than in group III (p=0.0097 and 0.026). 
Patients taking tamsulosin and alfuzosin had fewer pain attacks than did group III 
patients (1.24±0.57 vs. 1.43±0.67 vs. 1.75±1.17). Only 3 cases of drug side effects, 2 in 
group I and 1 in group II, were recorded.
Conclusions: The use of tamsulosin or alfuzosin for the medical treatment of lower ure-
teric stones proved to be safe and effective. Moreover, tamsulosin did not have any sig-
nificant benefits over alfuzosin.
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INTRODUCTION
Urolithiasis is a health problem of worldwide importance. 
Ureteral stones account for 20% of urolithiasis, and 70% 
of ureteral stones are located in the lower third of the 
ureter. It is generally believed that conservative medical 
treatment for ureteral stones should be applied first (which 
is also the wish of most patients). If conservative treatment 
is unsuccessful, shock wave lithotripsy (SWL) or uretero-
scopy (URS) can then be utilized [1]. The most important 
factors in predicting the likelihood of spontaneous stone 
passage are stone location and stone size [2]. For distal ure-
teral stones of 5 and 10 mm diameter, spontaneous ex-
pulsion occurs in 25% to 53% of cases [3].
　The simple watchful waiting approach can result in com-
plications, however, such as infection of the urinary tract, 
hydronephrosis, and renal function effects [4]. Therefore, 
the watchful waiting approach is extended by using phar-
macologic therapy, which can reduce symptoms and facili-
tate stone expulsion. One possible pathway for medical 
treatment is anti-inflammatory and anti-edematous treat-
ment by glucocorticoids. Another option is the relaxation 
of ureteral smooth muscle, e.g., by α1-adrenoceptor antag-
onists (α-blockers) or calcium channel blockers. A number 
of randomized clinical trials have tested these drugs, and 
the resulting findings have almost always been interpreted 
as proof of efficacy [5].
　The rationale behind the use of alpha blockers is that 
stimulation of the α1 receptors in the ureter increases the 
force of ureteral contraction and the frequency of ureteral Korean J Urol 2010;51:193-197
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peristalsis. Thus, blockade of α1 receptors inhibits basal 
tone, reduces peristaltic amplitude and frequency, and de-
creases intra-luminal pressure while increasing the rate 
of fluid transport. Alpha-1 blockers also induce an increase 
in the intra-ureteral pressure gradient around the stone 
that helps in stone expulsion [6]. Three subtypes of α1 re-
ceptor have been described, namely, α1a, α1b, and α1d. 
Among these, α1d receptors have the highest density in the 
distal ureter [7].
　Tamsulosin is the most commonly used α-blocker for the 
medical treatment of ureteric stones because of its ex-
cellent tolerability; the lack of need for dose titration upon 
initiation of treatment, which allows a fully effective dose 
to be administered right away; and its uroselectivity for 
α1a and α1d, resulting in relaxation of the smooth muscles 
of the lower ureter, facilitation of stone passage, and reliev-
ing of pain. However, limited direct comparative data in-
dicate that other α-blockers such as alfuzosin, doxazosin, 
and terazosin can be similarly effective [8,9].
　The main aim of this prospective study was to present 
our experience with the efficacy of tamsulosin and alfuzo-
sin in the medical treatment of symptomatic, uncom-
plicated distal ureteral stones.
MATERIALS AND METHODS
Patients presenting at the emergency department or urol-
ogy clinic at our institution with acute renal colic were eval-
uated for study participation in a prospective manner be-
tween March 2008 and November 2009. Distal ureteral 
stones were diagnosed on the basis of plain abdominal 
X-rays, urinary ultrasonography, and helical computed to-
mography when necessary. Additionally, the patients un-
derwent a series of measurements, including case history, 
physical examination, complete blood cell count, routine 
urinalysis, and serum creatinine measurement. The lower 
ureter was defined as the segment from the lower border 
of the sacroiliac joint to the vesico-ureteric junction. 
Patients ≥18 years of age with a single, unilateral ureteral 
stone of ≤10 mm were eligible for the study. Patients were 
excluded if they met any of the following criteria: (1) age 
less than 18 years, (2) pregnant or lactating women, (3) his-
tory of previous surgery on the ipsilateral ureter, (4) stone 
more than 10 mm, (5) multiple stones, (6) bilateral ureteric 
stones, (7) solitary kidney, (8) urinary tract infection, (9) 
moderate or severe hydronephrosis, (10) currently on 
α-blocker therapy, (11) known allergy to tamsulosin or al-
fuzosin, (12) contraindications for nonsteroidal anti-in-
flammatory agents (e.g., gastritis), or (13) renal insuffi-
ciency. All patients received a first treatment of Diclofenac 
75 mg by intramuscular injection, with a second dose after 
30 minutes if necessary. If Diclofenac gave inadequate 
pain relief, Tramal hydrochloride 100 mg by intramuscular 
injection was given. If the pain was resolved, the patient 
was dismissed and automatically enrolled in the study af-
ter providing informed written consent. The study protocol 
was approved by the ethics committee of our hospital.
　A total of 90 patients with distal ureteral stones ≤10 mm 
in diameter were randomly divided into 3 equal groups and 
given medications for 30 days. All patients in the 3 groups 
received diclofenac sodium (50 mg, tablet) every 12 hours 
for 1 week and then Diclofenac sodium injection (75 mg, 
amp) as needed, up to a maximum of 2 times per day. 
Patients in group I (n=30) received a daily oral dose of tam-
sulosin (0.4 mg), patients in group II (n=30) received a daily 
oral dose of alfuzosin (10 mg), and patients in group III 
(n=30) received Diclofenac sodium only. The study medi-
cations were discontinued after spontaneous stone ex-
pulsion, intervention, or at the end of the study period. 
Absences of stone expulsion at the end of the study or inter-
vention before the end of the study as the result of uncon-
trollable pain or adverse events were considered failed 
therapy.
　Follow-up visits were performed on a weekly basis. At the 
follow-up visit, every patient underwent urine analysis, se-
rum creatinine measurement, a plain X-ray KUB, and ab-
dominal ultrasonography. Also, patients were asked if they 
had seen any stone passage during urination. Abdominal 
CT was performed for patients with radiolucent stones if 
the stone was not expulsed by the end of study. For patients 
with a stone-free ureter on the last imaging study but un-
noticed stone expulsion, the date of last positive stone sta-
tus was recorded.
　The efficacy of treatment was evaluated in terms of rate 
and time of stone passage, frequency of pain attacks, and 
complications of medications.
1. Statistical analysis
Statistical analyses were performed with Student’s t-test, 
ANOVA, chi-square, and Fisher’s exact test by using the 
parameters of stone size, expulsion rate, time to expulsion, 
pain attacks, and side effects. The power used was 0.80, and 
the level of significance was 5%.
RESULTS
A total of 90 patients were enrolled in the study, and 87 pa-
tients completed the study (1 patient from group I and 2 pa-
tients from group III dropped out). Group I (29 patients) 
consisted of 19 men and 10 women (mean age: 40.7±14.8 
years), group II (30 patients) consisted of 18 men and 12 
women (mean age: 41.1±15.2 years), and group III (28 pa-
tients) consisted of 19 men and 9 women (mean age: 
38.9±13.3 years). The mean stone size was 4.97±2.24 mm 
for group I, 5.47±2.13 mm for group II, and 5.39±1.81 mm 
for group III. There were no statistically significant differ-
ences between the 3 groups in terms of sex, age, or stone 
size (p＞0.05). The baseline characteristics of the studied 
patients are summarized in Table 1.
　The results of the data analysis showed that 25 of 29 cases 
in group I (86.2%), 23 of 30 in group II (76.7%), and 14 of 
28 in group III (50%) expelled the stones by the end of the 
study. A significant statistical difference was noted be-
tween groups I and III (p=0.0028) and between groups II Korean J Urol 2010;51:193-197
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TABLE 1. Baseline characteristics of the studied patients
Variables
Group I (n=29) Group II (n=30) Group III (n=28)
p-value
Tamsulosin group Alfuzosin group Control group
No. of patients
Mean age (years)
Sex (male:female)
Stone size (mm)
Stone side right/left
29
40.7±14.8
1.5:1
4.97±2.24
13/16
30
41.1±15.2
1.9:1
5.47±2.13
16/14
28
38.9±13.3
2.1:1
5.39±1.81
15/13
ns
ns
ns
ns
−
ns: non-significant
TABLE 2. Expulsion rates, pain attacks, hospital readmission, and complications
Variables
Group I (n=29) Group II (n=30) Group III (n=28)
p-value
Tamsulosin group Alfuzosin group Control group
Stone expulsion rate at 30 days, no (%)
Expulsion rate for stone ≤5 mm (%)
Expulsion rate for stone ＞5 mm (%)
Expulsed stone size (mm)
Time of stone expulsion (days)
No. of pain attacks
Hospital readmission, no (%)
Overall complications
25 (86.2)
89.5
70
4.76±2.31
7.52±7.06
1.24±0.57
1 (3.4)
2 (6.9)
23 (76.7)
88.2
61.5
5.04±1.92
8.26±7.34
1.43±0.67 
2 (6.6)
1 (3.3)
14 (50)
73.3
23.1
4.43±1.22
13.9±6.99
1.75±1.17
4 (14.3)
0 (0)
0.0028 group I vs. III
0.035 group II vs. III
ns
0.024 group I vs. III
0.049 group II vs. III
ns
0.0097 group I vs. III
0.026 group II vs. III
0.042 group I vs. III
ns
ns
ns: non-significant
and III (p=0.035), whereas no significant difference was re-
corded between groups I and II (p=0.36). The mean size of 
the expulsed stones after the medical therapies was 
4.76±2.31 mm in group I, 5.04±1.92 mm in group II, and 
4.43±1.22 mm in group III. No statistical difference was ob-
served between the mean sizes of the expulsed stones in the 
3 groups (p＞0.05).
　For stones≤5 mm size, the expulsion rate was 89.5% of 
cases in group I, 88.2% in group II, and 73.3% in group III. 
No statistically significant differences were observed be-
tween the 3 groups (p＞0.05). For stones ＞5 mm size, the 
expulsion rate was 70% of cases in group I, 61.5% in group 
II, and 23.1% in group III. A significant statistical differ-
ence was noted between groups I and III (p=0.024) and be-
tween groups II and III (p=0.049), whereas no significant 
difference was recorded between groups I and II (p=0.69).
　The mean time to expulsion was 7.52±7.06 days (range, 
3-26 days) in group I, 8.26±7.34 days (range, 3-27 days) in 
group II, and 13.9±6.99 days (range, 5-27 days) in group III. 
A significant statistical difference was noted between 
groups I and III (p=0.0097) and between groups II and III 
(p=0.026), whereas no significant difference was recorded 
between groups I and II (p=0.72).
　Patients who did not subsequently expel the stone were 
scheduled for ureteroscopy or extracorporeal shock wave 
lithotripsy (ESWL). While awaiting intervention, 2 pa-
tients in group I and 1 patient in group II expelled their 
stones spontaneously (3, 9, and 7 days after therapy, re-
spectively), whereas no spontaneous expulsion of the stone 
was recorded in group III.
　Patients taking tamsulosin had fewer pain attacks than 
did patients in the other 2 groups (the mean number of pain 
attacks was 1.24±0.57 for group I patients, 1.43±0.67 for 
group II patients, and 1.75±1.17 for group III patients). A 
significant statistical difference was registered only be-
tween groups I and group III (p=0.042). There was no sig-
nificant difference in the number of pain attacks between 
patients in group I and group II (p=0.25) or between pa-
tients in group II and group III (p=0.21).
　No severe complications were recorded in the 3 groups. 
Two patients (6.9%) in group I recorded retrograde ejacu-
lation and 1 patient (3.3%) in group II recorded an episode 
of hypotension, which did not require suspension of the 
therapy. Hospital readmissions with consecutive inter-
vention and discontinuation of the medication due to un-
controllable pain occurred in 7 patients: 1 patient (3.4%) 
in group I, 2 patients (6.6%) in group II, and 4 patients 
(14.3%) in group III. The difference was not statistically 
significant (p＞0.05) (Table 2).
DISCUSSION
A variety of treatment options are available for the man-
agement of distal ureteral stones, including open ureter-Korean J Urol 2010;51:193-197
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olithotomy, ureteroscopic stone extraction, and shock 
wave lithotripsy. However, some argue that the patient 
should simply be observed to see if the stone will pass with-
out treatment. The literature provides a variety of results 
regarding spontaneous ureteral stone passage. Ueno et al 
evaluated more than 500 patients and reported a sponta-
neous stone expulsion rate of 57% for 5 mm calculi [4]. 
Kinder et al reported a 94% spontaneous expulsion rate for 
stones ≤5 mm and a 45% rate for calculi greater than that 
size [10].
　The decision for conservative medical treatment or ac-
tive interventional treatment is not based only on the over-
all probability of stone expulsion. For many patients, fac-
tors such as time for convalescence or reexposure to dread-
ed colics during conservative treatment make a consid-
erable impact on the decision to opt for an interventional 
treatment.
　There is currently a great deal of enthusiasm for ad-
juvant pharmacologic intervention to increase the ex-
pulsion rate and to reduce pain attacks and analgesic con-
sumption when a conservative therapy is considered. The 
drugs generally used in medical expulsive therapies for 
lower ureteric stones are calcium channel blockers, α- 
blockers, and corticosteroids [11-14].
　Most studies demonstrated a favorable benefit to tamsu-
losin and alfuzosin in facilitating stone passage, increasing 
the rate of stone expulsion, and decreasing pain and an-
algesic use, with only a few studies failing to find statisti-
cally significant differences between patients using and 
not using these drugs.
　Cervenakov et al in a randomized study registered a sig-
nificant statistical difference in the stone expulsion rate 
between the group treated with tamsulosin and the control 
group [15]. Similar results were reported in a study by 
Dellabella et al [16].
　De Sio et al published a study of 96 patients with distal 
ureteral stones to test the efficacy of tamsulosin as a medi-
cal expulsive therapy and found that patients taking tam-
sulosin achieved significantly higher rates of stone passage 
(90%) over a shorter time period (4.4 days) [17]. They also 
had lower analgesic use and fewer hospitalizations.
　In a double-blinded placebo-controlled trial conducted 
by  Pedro et al [18] on 76 patients to test the efficacy of alfu-
zosin as a medical expulsive therapy for distal ureteral 
stones, the authors concluded that alfuzosin improves the 
patient discomfort associated with stone passage and de-
creases the time to distal ureteral stone passage but does 
not increase the rate of spontaneous stone passage (77.1% 
for placebo and 73.5% for alfuzosin, p=0.83). In contrast, 
Agrawal et al recently published a placebo-controlled 
study of 102 patients with distal ureteral stones to compare 
the efficacy of alfuzosin and tamsulosin in the management 
of lower ureteral stones [8]. Patients were classified into 
3 equal groups. Group 1 patients (n=34) received 0.4 mg 
tamsulosin daily, group 2 patients (n=34) received 10 mg 
alfuzosin daily, and group 3 patients (n=34) received place-
bo (control group). Stone expulsion was observed in 82.3% 
in group 1, 70.5% in group 2, and 35.2% in group 3. The aver-
age expulsion time for groups 1, 2, and 3 was 12.3, 14.5, and 
24.5 days, respectively. The results of both study groups 
(groups 1 and 2) were superior to those of the placebo group 
(p=0.003 and p=0.001, respectively). The study failed to 
show any statistically significant differences between tam-
sulosin and alfuzosin regarding stone expulsion rate, ex-
pulsion time, or need for analgesic therapy. 
　In trials investigating the effecacy of α-blockers on ure-
teral stone expulsion with mean stone sizes ＜5 mm, only 
a few studies demonstrated a significantly higher ex-
pulsion rate in the treatment group [19,20]. In contrast, re-
garding α-blocker trials with stone sizes ≥5 mm, most of 
the studies demonstrated a significant benefit in stone ex-
pulsion rates [21].
　The present study was designed to compare and test the 
effectiveness of tamsulosin and alfuzosin on the manage-
ment of distal ureteric stones. Patients receiving tamsulo-
sin or alfuzosin were compared with patients receiving an-
algesic only as a control. The study was limited to patients 
with stone sizes of ≤10 mm. A maximum observation peri-
od of 30 days was chosen because a longer period can in-
crease the complication rate by 20% [22].
　Our results confirmed the efficacy of tamsulosin and al-
fuzosin for distal ureteric stones. A total of 86.2% of pa-
tients taking tamsulosin and 76.7% of patients taking alfu-
zosin were able to expel their stones at the end of study com-
pared with 50% of patients taking only analgesic. Patients 
taking tamsulosin and alfuzosin expelled the stones in sig-
nificantly fewer days. Tamsulosin and alfuzosin also de-
creased the frequency of pain attacks associated with stone 
passage. Tamsulosin did not have any significant benefits 
over alfuzosin.
　For stones ≤5 mm in size, the expulsion rate was 89.5 
of cases in group I, 88.2% in group II, and 73.3% in group 
III. No statistically significant differences were observed 
between the 3 groups (p＞0.05). For stones ＞5 mm in size, 
the expulsion rate was 70% of cases in group I, 61.5% in 
group II, and 23.1% in group III. A significant statistical 
difference was noted between groups I and III (p=0.024) 
and between groups II and III (p=0.049), whereas no sig-
nificant difference was recorded between groups I and II 
(p=0.69).
　Regarding the expulsion rate, we hypothesize that tam-
sulosin and alfuzosin are of more value in the treatment 
of distal ureteric stones ＞5 mm size than in the treatment 
of stones ≤5 mm in size. We believe that further studies 
using larger groups are needed to confirm these findings 
and to evaluate the effect on the stone expulsion rate of dif-
ferent variables such as age, sex, body mass index, later-
ality, location of the stone, and size of the stone . Thus, we 
advocate the need for multicentre trials.
　The most frequently reported adverse event with tamsu-
losin was transient hypotension [20]. No significant differ-
ence in adverse events was noted between tamsulosin 0.4 
mg and 0.2 mg. Pedro et al reported 12% adverse events in 
the alfuzosin group compared with 0% in the placebo group Korean J Urol 2010;51:193-197
Tamsulosin versus Alfuzosin Treatment for Distal Ureteral Stones 197
[18], whereas Yilmaz et al and Liatsikos et al reported no 
serious adverse events  [9,21].
　In the present study, minor therapy-related side effects 
were observed in 3 patients (2 patients taking tamsulosin 
developed retrograde ejaculation and 1 patient taking alfu-
zosin developed an episode of hypotension). The 3 patients 
were able to complete the study. No patients developed se-
rious side effects during the study period.
CONCLUSIONS
The use of tamsulosin and alfuzosin as a medical expulsive 
therapy for distal ureteric stones proved to be safe and ef-
fective as demonstrated by the increased stone expulsion 
rate, decreased expulsion time, and reduced pain attacks. 
Moreover, patients taking tamsulosin did not have any sig-
nificant benefits over patients taking alfuzosin. These 
drugs can be safely used for the management of un-
complicated distal ureteral stones before undertaking any 
invasive intervention.
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